Vertex Pharmaceuticals
VRTX
1,767 hedge funds and large institutions have $120B invested in Vertex Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 173 funds opening new positions, 709 increasing their positions, 631 reducing their positions, and 110 closing their positions.
57% more first-time investments, than exits
New positions opened: 173 | Existing positions closed: 110
12% more repeat investments, than reductions
Existing positions increased: 709 | Existing positions reduced: 631
4% more funds holding
Funds holding: 1,701 → 1,767 (+66)
1.52% more ownership
Funds ownership: 93.46% → 94.98% (+1.5%)
9% more call options, than puts
Call options by funds: $853M | Put options by funds: $783M
3% more capital inflows, than outflows
Capital inflows: $5.18B | Capital outflows: $5.04B
35% less funds holding in top 10
Funds holding in top 10: 17 → 11 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.24B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$331M |
| 3 |
SG Americas Securities
New York
|
+$207M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$197M |
| 5 |
Millennium Management
New York
|
+$194M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$725M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$395M |
| 3 |
Janus Henderson Group
London,
|
-$386M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$250M |
| 5 |
JP Morgan Chase
New York
|
-$228M |
VRTX Hedge Fund Activity: Q2 2026 in Review
1,767 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2026, worth a combined $120B — up 13% from $106B a quarter earlier.
Buyers outnumbered sellers: 173 funds opened new VRTX positions and 110 closed out — a net gain of 63 holders — while 709 added to existing stakes and 631 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.24B. The largest seller was Capital Research Global Investors, cutting an estimated $725M.
- 1,767 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2026, up from 1,701 in Q1 2026.
- Funds reported $120B of Vertex Pharmaceuticals stock for Q2 2026, up 13% quarter-over-quarter.
- 173 funds opened new Vertex Pharmaceuticals positions in Q2 2026 and 110 closed out, a net change of +63 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2026 was Franklin Resources, an estimated $1.24B added.
- The largest Vertex Pharmaceuticals seller in Q2 2026 was Capital Research Global Investors, an estimated $725M sold.
Based on aggregated 13F filings for Q2 2026.